stockrowRevvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
Follow RVTY
Alert me
Revvity Inc. (RVTY) Total debt
Revvity Inc.'s total debt at the end of fiscal 2025 was $3.2B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $2.6B. Over the past ten years it has ranged from $1.0B (fiscal 2015) to $5.0B (fiscal 2021); the current reading is higher than 73% of that period. Revvity Inc. ranks 9th of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $3.2B | 2.20% |
| FY2024 | $3.2B | (19.20%) |
| FY2023 | $3.9B | (11.26%) |
| FY2022 | $4.4B | (11.83%) |
| FY2021 | $5.0B | 150.37% |
| FY2020 | $2.0B | (4.02%) |
| FY2019 | $2.1B | 9.65% |
| FY2018 | $1.9B | (5.71%) |
| FY2017 | $2.0B | 91.71% |
| FY2016 | $1.0B | 3.31% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $2.6B | (17.82%) |
| Jun 2026 | $3.2B | (0.08%) |
| Mar 2026 | $3.2B | (0.38%) |
| Dec 2025 | $3.2B | 0.17% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $5.6B |
| LH Labcorp Holdings Inc. compare | $5.3B |
| ICLR ICON PLC compare | $3.4B |
| RVTY Revvity Inc. | $2.6B |
| CRL Charles River Laboratories International, Inc. compare | $2.4B |
| ILMN Illumina, Inc. compare | $1.8B |
| QGEN QIAGEN N.V. compare | $1.6B |
| GH Guardant Health, Inc. compare | $1.5B |
| MEDP Medpace Holdings, Inc. compare | $163.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on RVTY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement